ImmuPharma plc (LON:IMM – Get Free Report)’s stock price crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of GBX 6.20 and traded as low as GBX 5.50. ImmuPharma shares last traded at GBX 5.98, with a volume of 2,825,704 shares changing hands.
ImmuPharma Stock Down 0.7%
The company has a market capitalization of £29.86 million, a P/E ratio of -6.67 and a beta of 1.53. The firm has a fifty day simple moving average of GBX 9.40 and a 200-day simple moving average of GBX 6.20.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- How to Invest in Insurance Companies: A Guide
- ServiceNow’s $7 Billion Gamble: Panic or Opportunity?
- Best Stocks Under $10.00
- Dell and HP Are Raising Prices—And Investors Should Take Note
- Why Are These Companies Considered Blue Chips?
- Why DLocal Is the Top Emerging Market Fintech Stock to Watch for 2026
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
